SILVER SPRING, Md. - The FDA's Oncology Drugs Advisory Committee on Wednesday rejected Genta Inc.'s new drug application for Genasense (oblimersen sodium) to treat relapsed or refractory chronic lymphocytic leukemia, driving down the company's stock value for a second consecutive day. (BioWorld Today)